Equities Analysts Set Expectations for DNLI Q2 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities researchers at Zacks Research cut their Q2 2026 earnings per share (EPS) estimates for Denali Therapeutics in a report issued on Wednesday, October 23rd. Zacks Research analyst A. Chakraborty now forecasts that the company will post earnings per share of ($0.75) for the quarter, down from their previous forecast of ($0.74). The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.54) per share. Zacks Research also issued estimates for Denali Therapeutics’ Q3 2026 earnings at ($0.73) EPS and FY2026 earnings at ($2.90) EPS.

Other research analysts also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and issued a $90.00 target price on shares of Denali Therapeutics in a report on Wednesday, September 4th. JPMorgan Chase & Co. lowered their target price on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Raymond James reaffirmed a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Bank of America raised their price objective on Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Finally, Citigroup raised their price objective on Denali Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Denali Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $38.22.

Denali Therapeutics Stock Performance

DNLI stock opened at $26.15 on Friday. Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $32.13. The business’s 50-day moving average is $27.10 and its two-hundred day moving average is $22.81. The company has a market cap of $3.73 billion, a price-to-earnings ratio of -27.24 and a beta of 1.38.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, August 1st. The company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.09. The firm had revenue of $1.00 million during the quarter, compared to the consensus estimate of $10.00 million. During the same period in the prior year, the company posted $1.30 EPS. The firm’s revenue was down 99.7% compared to the same quarter last year.

Hedge Funds Weigh In On Denali Therapeutics

Several institutional investors have recently added to or reduced their stakes in DNLI. Capital Research Global Investors grew its holdings in Denali Therapeutics by 107.9% during the 1st quarter. Capital Research Global Investors now owns 6,049,957 shares of the company’s stock valued at $124,145,000 after buying an additional 3,140,429 shares in the last quarter. Baker BROS. Advisors LP grew its holdings in Denali Therapeutics by 43.1% during the 1st quarter. Baker BROS. Advisors LP now owns 3,731,695 shares of the company’s stock valued at $76,574,000 after buying an additional 1,124,499 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Denali Therapeutics during the 2nd quarter valued at approximately $24,454,000. Integral Health Asset Management LLC purchased a new position in shares of Denali Therapeutics in the 2nd quarter worth approximately $7,546,000. Finally, Candriam S.C.A. boosted its holdings in shares of Denali Therapeutics by 62.2% in the 2nd quarter. Candriam S.C.A. now owns 726,499 shares of the company’s stock worth $16,869,000 after purchasing an additional 278,621 shares during the period. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Insider Activity at Denali Therapeutics

In related news, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the sale, the director now owns 29,096 shares of the company’s stock, valued at approximately $844,656.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Ryan J. Watts sold 40,000 shares of Denali Therapeutics stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the sale, the chief executive officer now owns 235,807 shares of the company’s stock, valued at approximately $6,529,495.83. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steve E. Krognes sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $29.03, for a total value of $870,900.00. Following the transaction, the director now owns 29,096 shares of the company’s stock, valued at $844,656.88. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.90% of the stock is owned by corporate insiders.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.